This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 98/2/209    most recent 01.RES.0000200180.01710.e6v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teichert-Kuliszewska, K. Articles by Stewart, D. J. Search for Related Content PubMed PubMed Citation Articles by Teichert-Kuliszewska, K. Articles by Stewart, D. J. Related Collections Apoptosis Other hypertension Pulmonary circulation and disease Endothelium/vascular type/nitric oxide Related Article

(Circulation Research. 2006;98:209.)
© 2006 American Heart Association, Inc.

Molecular Medicine

Bone Morphogenetic Protein Receptor-2 Signaling Promotes Pulmonary Arterial Endothelial Cell Survival

Implications for Loss-of-Function Mutations in the Pathogenesis of Pulmonary Hypertension

Krystyna Teichert-Kuliszewska, Michael J.B. Kutryk, Michael A. Kuliszewski, Golnaz Karoubi, David W. Courtman, Liana Zucco, John Granton, Duncan J. Stewart

From the Terrence Donnelly Heart Center and Division of Cardiology (K.T.-K., M.J.B.K., M.A.K., G.K., D.W.C., L.Z., D.J.S.), St. Michael’s Hospital, Toronto; University Health Network (J.G.), Toronto; and the Departments of Medicine (M.J.B.K., J.G., D.J.S.) and Laboratory Medicine and Pathobiology (G.K., D.W.C., D.J.S.) and The McLaughlin Center for Molecular Medicine (M.J.B.K., D.J.S.), University of Toronto, Ontario, Canada.

Correspondence to Dr Duncan J. Stewart, Head, Division of Cardiology, St. Michael’s Hospital, 30 Bond St, Rm 6050 Queen Wing, Toronto, Ontario, Canada M5B 1W8. E-mail stewartd{at}smh.toronto.on.ca

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Mutations in the bone morphogenetic protein (BMP) receptor-2 (BMPR2) have been found in patients with idiopathic pulmonary arterial hypertension (IPAH); however, the mechanistic link between loss of BMPR2 signaling and the development of pulmonary arterial hypertension is unclear. We hypothesized that, contrary to smooth muscle cells, this pathway promotes survival in pulmonary artery endothelial cells (ECs) and loss of BMPR2 signaling will predispose to EC apoptosis. ECs were treated with BMP-2 or BMP-7 (200 ng/mL) for 24 hours in regular or serum-free (SF) medium, with and without addition of tumor necrosis factor , and apoptosis was assessed by flow cytometry (Annexin V), TUNEL, or caspase-3 activity. Treatment for 24 hours in SF medium increased apoptosis, and both BMP-2 and BMP-7 significantly reduced apoptosis in response to serum deprivation to levels not different from serum controls. Transfection with 5 µg of small interfering RNAs for BMPR2 produced specific gene silencing assessed by RT-PCR and Western blot analysis. BMPR2 gene silencing increased apoptosis almost 3-fold (P=0.0027), even in the presence of serum. Circulating endothelial progenitor cells (EPCs) isolated from normal subjects or patients with IPAH were differentiated in culture for 7 days and apoptosis was determined in the presence and absence of BMPs. BMP-2 reduced apoptosis induced by serum withdrawal in EPCs from normal subjects but not in EPCs isolated from patients with IPAH. These results support the hypothesis that loss-of-function mutations in BMPR2 could lead to increased pulmonary EC apoptosis, representing a possible initiating mechanism in the pathogenesis of pulmonary arterial hypertension.

Key Words: bone morphogenetic proteins • bone morphogenetic receptor-2 • pulmonary arterial hypertension • endothelial cells • endothelial progenitor cells • apoptosis

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Idiopathic pulmonary arterial hypertension (IPAH) is a rare and fatal disorder, with an estimated incidence of 1 to 2 per million cases per year¹ and a median survival from diagnosis of only 2.8 years. Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance (PVR) caused by vasoconstriction and excessive remodeling of small pulmonary arteries, resulting in widespread microvascular narrowing and obliteration.¹ Clinically, the pulmonary pathology in advanced PAH is characterized by abnormal muscularization of pulmonary arterioles, intimal thickening, and fibrosis,² as well as the presence of plexiform lesions,³ which are believed to result from dysregulation of endothelial cell (EC) growth.³

Although increased EC growth may be a feature of late stages of disease, there is increasing evidence that other mechanisms may predominate in early phases of PAH. In experimental models, blockade of EC growth factor receptors resulted in the potentiation of PAH and marked worsening the pathological vascular remodeling, even reproducing some of the "angioproliferative" features typical of advanced PAH.⁴ Interestingly, this effect could be reversed by inhibitors of apoptosis,⁴ suggesting that increased apoptosis of ECs in response to loss of survival signaling created conditions favoring the emergence of apoptosis-resistant cells with increased growth potential. Moreover, we have shown that overexpression of EC growth and survival factors, such as vascular endothelial growth factor (VEGF) and angiopoietin-1, prevented the development of monocrotaline-induced PAH,^5,6 an effect that was associated with reduced EC apoptosis. Together, the findings implicate EC apoptosis as a central mechanism in the initiation of PAH and suggest that pulmonary microvascular endothelium is dependent on tonic survival signaling, possibly more so than for other circulations.

The most significant advance in the understanding the pathogenesis of PAH has been the recent demonstration of germline mutations in the familial form of this disease that have been mapped to a single locus on chromosome 2q31-32.⁷ Mutations in the open reading frame of the bone morphogenetic protein (BMP) receptor-2 (BMPR2) gene were identified in &40% of familial PAH and in up to &15% of patients with no family history (ie, IPAH).^8–11 BMPR2 is a member of the transforming growth factor (TGF)-ß superfamily of transmembrane serine/threonine kinase receptors. More than 46 different mutations of BMPR2 have already been identified, some of which have been demonstrated to cause loss of the receptor function. However, how haploinsufficiency in this BMPR2 leads to pulmonary hypertension is unknown.

The ligands for the BMPR2 receptor represent a family of secreted growth factors known as the BMPs. Signal transduction through this pathway involves heterodimerization of BMPR2 with BMPR1, which results in phosphorylation of BMPR1, initiating activation of signal transduction. BMPs can have pleiotropic effects depending on the cell type, the specific ligand, and the environmental context.^12–14 For example, BMPs can inhibit proliferation and induce apoptosis in human pulmonary artery smooth muscle cells^15,16; however, in other cell types, including cardiomyocytes and epithelial cells, signaling via this pathway can have an opposite effect and promote cell survival.^17,18 Therefore, the role of BMPR2 in the normal lung may be complex, with different biological actions on different vascular cells, and its effect, particularly on pulmonary ECs and endothelial progenitor cells (EPCs) from patients with IPAH, has yet to be clarified.

The aim of the present study was to elucidate the effect of BMPR2 signaling on survival of pulmonary arterial ECs and EPCs isolated from normal subjects or patients with IPAH. We now show for the first time that BMP-2 and BMP-7 promoted survival of human pulmonary arterial ECs as well as EPCs isolated from normal subjects, consistent with a role of the BMPR2 signaling pathway in protecting pulmonary microvascular EC from apoptosis. In contrast, in EPCs isolated from IPAH patients, there was either reduced survival or even an accentuation in apoptosis in response to BMPs. These results suggest a new paradigm for loss-of-function BMPR2 mutations in the pathogenesis of PAH, contributing to the initial endothelial microvascular loss, as well as potentiating reactive arterial remodeling in the remaining arteriolar and arterial bed.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cell Culture and Experimental Design
Human pulmonary artery ECs (HPAECs) were obtained from (Cambrex) and grown in EBM-2 (SingleQuot Media BulletKit, Cambrex) supplemented with 2% fetal bovine serum. All experiments were performed using subconfluent cultures (&80%), of the same batch, derived from pooled donors, and used only between passages 3 to 4. Culture conditions for other cell types are described in the online data supplement available at http://circres.ahajournals.org. To induce apoptosis, cells were exposed to tumor necrosis factor (TNF)- (20 ng/mL; R&D) or serum withdrawal for 24 hours in the presence or absence of BMP-2 or BMP-7 (200 ng/mL; R&D). Cells were pretreated with BMPs for 2 hours before exposure to TNF. After treatment, cells were either suspended for flow cytometric analysis, fixed and stained (TUNEL) for microscopic analysis, or lysed for caspase-3 activity assays.

Apoptosis Assays
Apoptosis was assessed by 3 independent methods.

Flow Cytometry
Apoptotic and necrotic cell death was assessed in HPAECs by flow cytometric analysis (Annexin V-FLUOS Staining Kit, Roche) under control or apoptosis-inducing conditions, in the presence or absence of BMPs. At the end of the treatment period, cells were suspended by a brief trypsinization (0.05% with EDTA) and washed twice with cold PBS. Cells were then resuspended in 100 µL of 1x binding buffer with 2 µL of Annexin V–fluorescein isothiocyanate (FITC) and 2 µL of propidium iodide (PI). The cells were gently mixed and incubated for 15 minutes at room temperature in the dark, and then 400 µL of 1x binding buffer was added to each tube before analysis. Fluorescence was induced with the 488-nm argon laser and monitored at 512 nm (FL1) and 543 nm (FL3) on a Beckman Coulter Cytomics FC500 analyzer.

TUNEL Staining
After the various treatments, cells were fixed in 2% paraformaldehyde in PBS for 10 minutes and washed 3 times with PBS, permeabilized with 0.2% Triton-X, and stained using the Dead/End Fluorometric apoptosis detection system (Promega), following the instructions of the manufacturer, producing fluorescein TUNEL staining and PI nuclear counterstaining. Merged images were generated by dual scanning at 488 nm and 543 nm with a confocal microscope (Bio-Rad, Radiance 2100) and TUNEL-positive or -negative cells were counted in 6 random fields per well in a blinded fashion.

Caspase-3 Activity
A fluorometric assay kit (Promega) was used for detection of activated caspase-3. Freeze/thaw cytosolic extracts were incubated at 30°C with the fluorgenic substrate, 7-amino-4methyl coumarin (Ac-DEVD-AMC) in 96-well microliter plates, and emission fluorescence was detected at 460 nm after excitation at 360 nm. Results were calculated from a standard curve per the instructions of the manufacturer. Activated caspase-3 was also assessed by Western analysis as described in the online data supplement.

Silencing of BMPR2 mRNA
Gene silencing of BMPR2 was achieved using small interfering RNA (siRNA) as described by Elbashir and colleagues^19,20 (see online data supplement). Forty-eight to 72 hours after transfection, HPAECs were lysed with 100 µL of sodium dodecyl sulfate (SDS) sample buffer (10 mmol/L Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 0.4% dithiothreitol, 1 mmol/L orthovanadate), and BMPR2 expression was assessed by semiquantitative RT-PCR and Western blot analysis, as described in the online data supplement.

Isolation and Differentiation of EPCs
All use of human material was approved by the Research Ethics Boards at St. Michael’s Hospital and the University Health Network. EPCs were isolated from peripheral blood as described previously.²¹ Briefly, peripheral venous blood was obtained from 16 patients with IPAH recruited from the Pulmonary Hypertension clinic (age 45±13 years, 15 women; see Table) or 5 normal subjects (age 38±11 years, 4 women) after written informed consent. The mononuclear cell fraction was isolated by Ficoll–Paque density gradient (Becton Dickinson) centrifugation and washed 3 times with PBS, and cells were plated at a density of 1.5x10⁶ mononuclear cells/mL on fibronectin-coated culture slides (Becton Dickinson) in basal medium-2 (EBM-2; Cambrex) supplemented with 5% FBS, with human VEGF-A, fibroblast growth factor-2, epidermal growth factor, insulin-like growth factor-1, and ascorbic acid (EGM-2 MV SingleQuot Media BulletKit; Cambrex). Cells were grown for 7 days with culture media changes every 48 hours and then characterized as described in the online data supplement. EPCs were treated with BMP-2 (200 ng/mL) for 24 hours in EGM-2 medium in the presence or absence of 5% FBS, and the number of cells undergoing apoptosis was determined by flow cytometry.

View this table: [in this window] [in a new window]   Table 1. Patient Characteristics

Statistical Analysis
Data are presented as mean±SEM. Significance of differences was assessed using ANOVA followed by post hoc unpaired t test, unless otherwise specified. The significance of relationships between variables was assessed using linear regression. A value of P<0.05 was considered statistically significant. All analyses were conducted using InStat (Prism) software.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Effect of BMPR2 Ligands on EC Survival
Exposure of HPAECs for 24 hours to SF medium significantly increased apoptosis (Figure 1A and 1B, a and b). Addition of BMP-2 or -7 (200 ng/mL) markedly reduced the number of the cells undergoing apoptosis in response to serum withdrawal (c and d). Figure 1C presents summary data of the results of 5 experiments showing that serum withdrawal produced a significant increase in Annexin V staining in cultured HPAECs, which could be largely prevented by the addition of either BMP-2 or -7 for 24 hours. Consistent with these results, we also observed that BMP-2 protected against apoptosis induced by TNF- assessed by TUNEL staining (Figure 2A and 2B). In separate experiments, treatment with BMP-7 also significantly reduced apoptosis in response to serum deprivation from 23.85±1.20% to 1.98±0.54% (P<0.05). Similarly, caspase-3 activity in response to serum deprivation was significantly reduced in cells treated with both BMP-2 and -7 compared with control cells in SF conditions (Figure 2C). Moreover active caspase-3, assessed by the presence of cleaved 19 and 17 kDa subunits by Western blot analysis, was reduced by BMP-2 and -7 treatment compared with control cells in SF conditions, as show on representative blot (Figure 3A) and summary data (Figure 3B), again confirming that treatment with BMP-2 or -7 for 24 hours markedly reduced apoptosis. A similar protective effect in response to BMP-2 and BMP-7 was seen in human arterial endothelial cells (HAEC) (supplemental Figure I).

View larger version (25K): [in this window] [in a new window]   Figure 1. Cells were labeled with Annexin V-FITC and PI, and apoptosis was assessed by flow cytometry. A, Histogram of the shift of the cell population in SF conditions comparing with control. B, Representative scatter plots of PI (y-axis) vs Annexin V-FITC (x-axis). Control (a), SF condition (b), BMP-2 (c), and BMP-7 (d). Absence of both markers (lower left quadrants) indicates viable cells; PI positive alone (upper left quadrants) indicates cellular necrosis, whereas Annexin V staining alone or together with PI (upper right and lower right quadrants) is indicative of early- and late-stage apoptosis, respectively. C, Summary data of 5 experiments showing the effect of BMP-2 or BMP-7 for 24 hours in SF medium. *P<0.05 vs FCS, P<0.05 vs SF.

View larger version (22K): [in this window] [in a new window]   Figure 2. A, Confocal images of HPAECs exposed to TNF- (20 ng/mL) for 24 hours either in the absence (a) or presence (b) of BMP-2 (200 ng/mL). TUNEL-positive cell nuclei exhibit bright green fluorescence as opposed to the red fluorescence of the PI nuclear counterstain, whereas colocalization of TUNEL and PI staining appears as yellow (see inset). B, Summary data of 4 experiments showing the proportion of TUNEL-positive nuclei in TNF-–treated cells with or without BMP-2. C, Caspase-3 activity determined in HPAECs following 24 hours in SF conditions without or with treatment with BMP-2 or -7. P<0.05 vs SF (n=4 experiments).

View larger version (26K): [in this window] [in a new window]   Figure 3. A, Western blot showing the presence of cleaved caspase-3 subunits at 19 and 17 kDa and total caspase-3 as a 34-kDa protein. B, Quantification of Western blots for active caspase-3, (19 or 17 kDa/34-kDa band density) showing a significant increase in activated caspase-3 in SF conditions. Following treatment with BMP-2 or BMP-7 for 24 hours, there was a significant decrease in activated caspase-3 levels. *P<0.05 vs SF, #P<0.05 vs control. Light bars, 19 kDA; dark bars, 17 kDa (n=3 experiments).

Effect of Reduced BMPR2 Expression on EC Survival
To explore whether the protective effects of BMPs were indeed mediated through BMPR2 signaling, we used specific silencing siRNA to knockdown BMPR2 expression (Figure 4). Forty-eight hours after transfection with siRNA, a >50% knockdown of BMPR2 protein expression relative to ß-actin was observed by Western analysis, whereas there was no effect of the nonsilencing siRNA (data not shown). Transfection with siRNA for lamin A/C, used as positive control, resulted in the level of inhibition as described by Qiagen (data not shown). Inhibition of BMPR2 receptor expression using specific siRNA significantly increased apoptosis in HPAECs cultured in the presence of serum (Figure 5), confirming the important role of this pathway in mediating EC survival signaling under basal conditions.

View larger version (47K): [in this window] [in a new window]   Figure 4. A, RT-PCR analysis of BMPR2 and GAPDH in HPAECs showing silencing of BMPR2 mRNA expression after transfection with siRNA for BMPR2 with no change in the amplified product for GAPDH. B, Representative Western blots showing BMPR2 protein inhibition following transfection with the specific silencing siRNA after 48 hour. C, Summary data of 4 experiments showing the protein level of BMPR2 normalized to the level of ß-actin in control cells, after transfection with silencing siRNA for BMPR2 receptor. *P<0.05 vs control by unpaired t test.

View larger version (33K): [in this window] [in a new window]   Figure 5. HPAECs were transfected with BMPR2 silencing siRNA, and 48 hours later the cells were labeled with Annexin V-FITC and PI and analyzed by fluorescence-activated cell sorting. A, Representative scatter plots for control HPAECs (a) or siRNA-transfected cells either with a nonsilencing sequence (NS) (b) or with the BMPR2 silencing siRNA (c). B, Summary data from 6 experiments showing that inhibition of BMPR2 receptor expression increased apoptosis by more then 2-fold. *P<0.05 vs control.

Effect of BMPs on Endothelial Progenitor Cells
In the next series of experiments, we examined the functional significance of these findings using EPCs isolated from the circulating blood of patients with IPAH. EPCs represent an accessible source of cells that can be differentiated to an endothelial phenotype²¹ and thus can provide a useful surrogate for somatic human endothelial cells. After 7 days in differential culture, EPCs exhibited a typical endothelial-like morphology (Figure 6A, a), and >80% of cells were positive for EC markers including Tie2, VEGFR2, and UEA-1 lectin (Figure 6, b and d, respectively). EPCs from patients were qualitatively similar to those from normal controls, and neither showed evidence of differentiation to myofibroblast lineage under the conditions studied (supplemental Figure II).

View larger version (28K): [in this window] [in a new window]   Figure 6. A, Cells were plated on fibronectin-coated slides and grown in EBM-2 MV medium for 7 days, and EPC differentiation was determined by immunohistochemistry. EPCs exhibited typical endothelial-like morphology, as shown in this phase contrast image (a). Cells were stained for the endothelial makers including Tie2 (b), VEGFR-2 (c), and UEA-1 (d) and examined by confocal microscopy. Eighty to ninety percent of cells were positive for the above markers after 7 days in culture. B, EPCs from control subjects and IPAH patients were exposed to BMP-2 (200 ng/mL, 24 hours) in SF medium, and the number of cells undergoing apoptosis was analyzed by fluorescence-activated cell sorting. C, Response to BMP-2 under SF conditions on EPCs isolated IPAH patients is shown on y-axis as percent change in apoptosis plotted against mean of pulmonary arterial pressure (mPAP) on the x-axis. *P<0.05 vs SF, no BMP-2; P<0.05 vs normal.

There was no significant difference in basal rates of apoptosis in EPCs from patients with IPAH versus normal controls 24 hours of serum withdrawal (21.06±2.89% versus 14.58±3.05%, respectively), although there was a tendency toward slightly higher rates in IPAH cells when grown in the presence of serum (7.69±2.04% versus 3.18±0.71%, respectively). However, with the addition of BMP-2, EPCs from control subjects showed a highly significant reduction in the rate of apoptosis (&50% inhibition, Figure 6B) consistent with a protective effect of BMP/BMPR2 signaling in a manner analogous the normal HPAECs. In contrast, the protective effect of BMP-2 was markedly altered in EPCs derived from IPAH patients compared with those isolated from normal subjects. Although some patients exhibited weak protection, the majority demonstrated a paradoxical increase in apoptosis in response to BMP-2, and overall this response was significantly different from cells derived from normal subjects (P=0.02). Interestingly, the magnitude of response to BMP-2 was associated with the hemodynamic severity the PAH (P<0.05), such that the patients with the highest PAP exhibited the most dramatic increase in apoptosis (Figure 6C).

Expression of BMPR2 Receptor by Human EPCs
We assessed BMPR2 receptor expression to determine whether the heterogeneous response to BMP-2 in EPCs from patients with PAH might be attributable to varying levels of receptor expression. Cells from both control subjects and patients with PAH showed similar patterns of BMPR2 expression by immunostaining (Figure 7A). Moreover, there were no significant differences in mean BMPR2 mRNA levels assessed by quantitative RT-PCR between EPCs from PAH patients and controls (Figure 7B), although there was considerable individual variation, with some patients exhibiting reduced expression and others exhibited levels up to 2- to 3-fold higher than the mean. However, when BMPR2 mRNA expression was plotted against magnitude of apoptosis in response to BMP-2, no relationship was seen (Figure 7C).

View larger version (19K): [in this window] [in a new window]   Figure 7. A, BMPR2 protein was visualized in EPCs from patients with PAH by staining with anti-human polyclonal BMPR2 antibody following Alexa Fluor 488 anti-goat secondary antibody (green), with nuclear counterstain with TO-PRO (blue). B, BMPR2 receptor expression in EPCs obtained from control subjects and patients with IPAH evaluated by quantitative RT-PCR using TaqMan probe and primers specific for BMPR2, normalized to GAPDH levels. Values shown are mean of triplicate measurements, expressed in arbitrary units relative to the expression of BMPR2 in EPCs from normal controls (normalized to 1.0) (n=16). *P>0.05 vs control. C, mRNA expression levels in individual patients did not correlate with the magnitude of apoptosis in response to BMP-2 treatment.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
This is the first demonstration that the BMP/BMPR2 pathway protects against EC apoptosis, which is in sharp contrast to its well-established proapoptotic and growth inhibitory effects in smooth muscle cell (SMC) lines. In this report, we show that BMPs decreased apoptosis in response to serum deprivation and TNF-, whereas knockdown of the BMPR2 using siRNA increased the basal level of apoptosis in normal HPAECs. Moreover, defects in this pathway may be relevant clinically, because we also show altered response to BMP-2 in EPCs isolated from patients with IPAH compared with those from normal subjects. These observations may have important implications regarding the link between mutations in the BMPR2 gene and the development of disease and suggest that, in addition to dysregulated SMC growth, patients with this mutation may be more susceptible to EC loss, which has now been implicated as an initiating event in the pathogenesis of PAH in various experimental models.^4,22

The recent identification of the association between mutations of the BMPR2 receptor and idiopathic PAH,^8,11,23,24 both familial and sporadic, represents a major advance toward an understanding of the complex pathogenic mechanisms that underlie this fatal disease. Although BMPR2 is expressed by both pulmonary artery endothelial and SMCs, most investigations have focused on the potential importance of BMPR2 mutations on SMCs²⁵ and a clear picture has emerged that BMP signaling represents an inhibitory pathway, which prevents excessive pulmonary arterial muscularization by reducing SMC growth and increasing apoptosis.^15,16 However, if anything BMPR2 is found to a greater extent on the pulmonary vascular endothelium than in the surrounding SMCs.²⁶ Moreover, lung vascular endothelium has been recently reported to exhibit high levels of activation of downstream signaling molecules (ie, SMADs),²⁷ further implicating the endothelial BMPR2 system in this disease. PAH has also been described in patients harboring mutations in endothelial restricted gene, the ALK-1, another member of the TGF family of receptors.^28–30 These mutations that are well known to be associated with arteriovenous malformations that are characteristic of hereditary hemorrhagic telangiectasia (HHT).^28,29 The fact that mutations in an endothelial-restricted gene have now been linked to IPAH further implicates the endothelium as a critical target in the molecular pathogenesis of this disease. Therefore, the elucidation of the functional importance of BMP signaling in ECs as opposed to SMCs may provide important insight into the mechanisms whereby mutations of this receptor result in predisposition for PAH.

Our results strongly suggest that BMPs protect against apoptosis in HPAECs, which support a role for the BMPR2 pathway in survival signaling in normal human pulmonary endothelium. Therefore, mutations in the BMPR2 receptor, and possibly other related pathways, may lead to increased EC loss in response to environmental triggers. Loss of microvascular endothelium, particularly at the level of the fragile precapillary arterioles, which consist of little more than endothelial tubes, could result loss of continuity of distal arterioles, thus progressively excluding portions of the microvasculature from the pulmonary circulation.⁶ Indeed, we have shown that loss of precapillary arteriolar continuity precedes the development of PAH in the monocrotaline model and that gene transfer of EC survival factors such as VEGF and angiopoietin-1, prevented the development pulmonary vascular disease.^5,6 Similarly, inhibition of VEGF signaling was reported to result in marked potentiation of PAH in the chronic hypoxic model, associated with exaggerated vascular remodeling and evidence of angioproliferative lesions.⁴ Interestingly, this was completely rescued by the use of the caspase inhibitor, Z-Asp,^4,22 again suggesting that EC apoptosis plays a central role in this model.

In this report, we also examined the effect of BMPs on survival of EPCs harvested from the circulating blood of patients with IPAH compared with normal subjects. Increasingly, it is recognized that these bone marrow–derived cells circulate postnatally in the peripheral blood and are believed to home to regions of the vasculature with injured endothelial lining, and a variety of diseases are characterized by alterations in the number or quality of circulating EPCs.^31–34 The present data show that EPCs from patients with IPAH are abnormal in terms of their response to BMPs. Although the mutation status of our PAH cohort is not known, it is likely that the majority of these patients with sporadic disease would not harbor a mutation in the BMPR2 gene.³⁵ A reduction in the survival in response to BMP-2 is consistent with a possible downregulation of receptor expression, as has been previously reported in the pulmonary vasculature of patients with IPAH.²⁶ However, we saw no overall reduction in BMPR2 expression in EPCs from patients with IPAH compared with normal controls. Rather, the increase in apoptosis, which was seen in cells from the majority of patients, is consistent with abnormal signaling in response to BMPs, as was described in SMCs of patients with IPAH.^36,37 Of note, there was a significant correlation between the degree of EPC apoptosis induced by BMP and the severity of hemodynamic abnormality in the pulmonary bed. Although this might indicate that patients exhibiting this response were predisposed to develop severe PAH, we cannot exclude a confounding effect of hemodynamic factors (ie, increased shear forces) or concomitant drug therapy (ie, epoprostenol).

Nevertheless, the present results suggest that mutations of BMPR2, and possibly related genes as well, could lead to diametrically opposite consequences in ECs and SMCs, which may both contribute importantly to the development of PAH (supplemental Figure III). In pulmonary endothelium, loss of BMPR2 signaling may increase the susceptibility to programmed cell death in response to injurious environmental stress, particularly at the level of the distal "precapillary" arterioles. EC apoptosis could be an initiating mechanism for IPAH, leading directly to microvascular obliteration, as a result of degeneration of these fragile endothelial structures.³⁸ Alternatively, repeated waves of EC loss may indirectly result in a reactive increase in proliferation of the remaining endothelium and provide conditions favoring the emergence of apoptosis-resistant, hyperproliferative ECs, which is characteristic of the later stages of this disease.³⁹ In contrast, the same mutation in pulmonary SMCs will result in the loss of inhibitory regulation of cell growth, thus amplifying medial hypertrophy occurring in response to abnormal pulmonary hemodynamics and increased vasoconstrictor/growth factor expression (ie, serotonin and endothelin).⁴⁰ Taken together, this paradigm may help explain why the lung is uniquely susceptible to extreme vascular remodeling resulting from haploinsufficiency in a growth and differentiation receptor that is ubiquitously expressed in all tissues throughout the body.

	Acknowledgments

 
This work was supported by research grant from the Canadian Institutes of Health Research (MOP-57726) and by Northern Therapeutics Inc. D.J.S is a member of the Richard Lewar Center of Excellence. We thank Mary McCarthy from the Pulmonary Hypertension Clinic for her valuable assistance, and Judy Trogadis and Xian Kang for important technical contributions.

	Footnotes

 
D.J.S. is a principal and Chief Scientific Officer of Northern Therapeutics Inc, and this work was funded in part by Northern Therapeutics. D.W.C. provides consulting services and advice on experimental and clinical trial design to Northern Therapeutics, which develops cell-based gene transfer technologies for the treatment of primary pulmonary hypertension.

Original received March 4, 2005; resubmission received October 24, 2005; accepted December 1, 2005.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997; 336: 111–117.[Free Full Text]
2. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen LA, Park K, Friedman PJ. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med. 2000; 162: 1577–1586.[Abstract/Free Full Text]
3. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol. 1999; 155: 411–419.[Abstract/Free Full Text]
4. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc MG, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001; 15: 427–438.[Abstract/Free Full Text]
5. Campbell AI, Zhao Y, Sandhu R, Stewart DJ. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation. 2001; 104: 2242–2248.[Abstract/Free Full Text]
6. Zhao YD, Campbell AI, Robb M, Ng D, Stewart DJ. Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res. 2003; 92: 984–991.[Abstract/Free Full Text]
7. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND, Siemieniak DR, Wheeler L, Phillips JA III, Newman JH, Conneally PM, Ginsburg D, Loyd JE. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32. Nat Genet. 1997; 15: 277–280.[CrossRef][Medline] [Order article via Infotrieve]
8. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 2000; 26: 81–84.[CrossRef][Medline] [Order article via Infotrieve]
9. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000; 37: 741–745.[Abstract/Free Full Text]
10. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA III, Newman J, Williams D, Galie N, Manes A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris P, Humbert M, Donnai D, Martensson G, Tranebjaerg L, Loyd JE, Trembath RC, Nichols WC. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet. 2001; 68: 92–102.[CrossRef][Medline] [Order article via Infotrieve]
11. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000; 67: 737–744.[CrossRef][Medline] [Order article via Infotrieve]
12. Yokouchi Y, Sakiyama J, Kameda T, Iba H, Suzuki A, Ueno N, Kuroiwa A. BMP-2/-4 mediate programmed cell death in chicken limb buds. Development. 1996; 122: 3725–3734.[Abstract]
13. Iwasaki S, Iguchi M, Watanabe K, Hoshino R, Tsujimoto M, Kohno M. Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2. J Biol Chem. 1999; 274: 26503–26510.[Abstract/Free Full Text]
14. Bhatia M, Bonnet D, Wu D, Murdoch B, Wrana J, Gallacher L, Dick JE. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J Exp Med. 1999; 189: 1139–1148.[Abstract/Free Full Text]
15. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ, Yuan JX. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003; 285: L740–L754.[Abstract/Free Full Text]
16. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation. 2001; 104: 790–795.[Abstract/Free Full Text]
17. Izumi M, Fujio Y, Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, Oshima Y, Nakaoka Y, Kishimoto T, Yamauchi-Takihara K, Hirota H. Bone morphogenetic protein-2 inhibits serum deprivation-induced apoptosis of neonatal cardiac myocytes through activation of the Smad1 pathway. J Biol Chem. 2001; 276: 31133–31141.[Abstract/Free Full Text]
18. Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell. 2001; 12: 3328–3339.[Abstract/Free Full Text]
19. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411: 494–498.[CrossRef][Medline] [Order article via Infotrieve]
20. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15: 188–200.[Abstract/Free Full Text]
21. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–967.[Abstract/Free Full Text]
22. Taraseviciene-Stewart L, Gera L, Hirth P, Voelkel NF, Tuder RM, Stewart JM. A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J Physiol Pharmacol. 2002; 80: 269–274.[CrossRef][Medline] [Order article via Infotrieve]
23. Machado RD, James V, Southwood M, Harrison RE, Atkinson C, Stewart S, Morrell NW, Trembath RC, Aldred MA. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation. 2005; 111: 607–613.[Abstract/Free Full Text]
24. Harrison RE, Berger R, Haworth SG, Tulloh R, Mache CJ, Morrell NW, Aldred MA, Trembath RC. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation. 2005; 111: 435–441.[Abstract/Free Full Text]
25. De Caestecker M, Meyrick B. Bone morphogenetic proteins, genetics and the pathophysiology of primary pulmonary hypertension. Respir Res. 2001; 2: 193–197.[CrossRef][Medline] [Order article via Infotrieve]
26. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002; 105: 1672–1678.[Abstract/Free Full Text]
27. Richter A, Yeager ME, Zaiman A, Cool CD, Voelkel NF, Tuder RM. Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 170: 1340–1348.[Abstract/Free Full Text]
28. Abdalla SA, Gallione CJ, Barst RJ, Horn EM, Knowles JA, Marchuk DA, Letarte M, Morse JH. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J. 2004; 23: 373–377.[Abstract/Free Full Text]
29. Abdalla SA, Cymerman U, Johnson RM, Deber CM, Letarte M. Disease-associated mutations in conserved residues of ALK-1 kinase domain. Eur J Hum Genet. 2003; 11: 279–287.[CrossRef][Medline] [Order article via Infotrieve]
30. Cymerman U, Vera S, Karabegovic A, Abdalla S, Letarte M. Characterization of 17 novel endoglin mutations associated with hereditary hemorrhagic telangiectasia. Hum Mutat. 2003; 21: 482–492.[CrossRef][Medline] [Order article via Infotrieve]
31. Luttun A, Carmeliet G, Carmeliet P. Vascular progenitors: from biology to treatment. Trends Cardiovasc Med. 2002; 12: 88–96.[CrossRef][Medline] [Order article via Infotrieve]
32. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol. 2004; 44: 1690–1699.[Abstract/Free Full Text]
33. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004; 95: 343–353.[Abstract/Free Full Text]
34. Dimmeler S, Zeiher AM. Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? J Mol Med. 2004; 82: 671–677.[CrossRef][Medline] [Order article via Infotrieve]
35. Morse JH, Deng Z, Knowles JA. Genetic aspects of pulmonary arterial hypertension. Ann Med. 2001; 33: 596–603.[Medline] [Order article via Infotrieve]
36. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, Atkinson C, Chen H, Trembath RC, Morrell NW. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005; 96: 1053–1063.[Abstract/Free Full Text]
37. Stewart DJ. Bone morphogenetic protein receptor-2 and pulmonary arterial hypertension: unraveling a riddle inside an enigma? Circ Res. 2005; 96: 1033–1035.[Free Full Text]
38. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells. Efficacy of combined cell and eNOS gene therapy in established disease. Circ Res. 2005; 96: 442–450.[Abstract/Free Full Text]
39. Voelkel NF, Cool C, Taraceviene-Stewart L, Geraci MW, Yeager M, Bull T, Kasper M, Tuder RM. Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med. 2002; 30: S251–S256.[CrossRef][Medline] [Order article via Infotrieve]
40. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001; 108: 1141–1150.[CrossRef][Medline] [Order article via Infotrieve]

Related Article:

Spatio-Temporal Diversity of Apoptosis Within the Vascular Wall in Pulmonary Arterial Hypertension: Heterogeneous BMP Signaling May Have Therapeutic Implications

Evangelos D. Michelakis
Circ. Res. 2006 98: 172-175. [Full Text] [PDF]

This article has been cited by other articles:

				E. D. Michelakis, M. R. Wilkins, and M. Rabinovitch Emerging Concepts and Translational Priorities in Pulmonary Arterial Hypertension Circulation, September 30, 2008; 118(14): 1486 - 1495. [Full Text] [PDF]

				K.-H. Hong, Y. J. Lee, E. Lee, S. O. Park, C. Han, H. Beppu, E. Li, M. K. Raizada, K. D. Bloch, and S. P. Oh Genetic Ablation of the Bmpr2 Gene in Pulmonary Endothelium Is Sufficient to Predispose to Pulmonary Arterial Hypertension Circulation, August 12, 2008; 118(7): 722 - 730. [Abstract] [Full Text] [PDF]

				Y. Song, L. Coleman, J. Shi, H. Beppu, K. Sato, K. Walsh, J. Loscalzo, and Y.-Y. Zhang Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H677 - H690. [Abstract] [Full Text] [PDF]

				K. Asosingh, M. A. Aldred, A. Vasanji, J. Drazba, J. Sharp, C. Farver, S. A.A. Comhair, W. Xu, L. Licina, L. Huang, et al. Circulating Angiogenic Precursors in Idiopathic Pulmonary Arterial Hypertension Am. J. Pathol., March 1, 2008; 172(3): 615 - 627. [Abstract] [Full Text] [PDF]

				D. B. Frank, J. Lowery, L. Anderson, M. Brink, J. Reese, and M. de Caestecker Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L98 - L109. [Abstract] [Full Text] [PDF]

				S. Gu, J. He, W.-T. Ho, S. Ramineni, D. M. Thal, R. Natesh, J. J. G. Tesmer, J. R. Hepler, and S. P. Heximer Unique Hydrophobic Extension of the RGS2 Amphipathic Helix Domain Imparts Increased Plasma Membrane Binding and Function Relative to Other RGS R4/B Subfamily Members J. Biol. Chem., November 9, 2007; 282(45): 33064 - 33075. [Abstract] [Full Text] [PDF]

				A. Zakrzewicz, M. Hecker, L. M. Marsh, G. Kwapiszewska, B. Nejman, L. Long, W. Seeger, R. T. Schermuly, N. W. Morrell, R. E. Morty, et al. Receptor for Activated C-Kinase 1, a Novel Interaction Partner of Type II Bone Morphogenetic Protein Receptor, Regulates Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension Circulation, June 12, 2007; 115(23): 2957 - 2968. [Abstract] [Full Text] [PDF]

				P. B. Sehgal, S. Mukhopadhyay, F. Xu, K. Patel, and M. Shah Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1526 - L1542. [Abstract] [Full Text] [PDF]

				Y. Tada, S. Majka, M. Carr, J. Harral, D. Crona, T. Kuriyama, and J. West Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1556 - L1563. [Abstract] [Full Text] [PDF]

				A. M. Reynolds, W. Xia, M. D. Holmes, S. J. Hodge, S. Danilov, D. T. Curiel, N. W. Morrell, and P. N. Reynolds Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1182 - L1192. [Abstract] [Full Text] [PDF]

				M. Levy, C. Maurey, D. S. Celermajer, P. R. Vouhe, C. Danel, D. Bonnet, and D. Israel-Biet Impaired Apoptosis of Pulmonary Endothelial Cells Is Associated With Intimal Proliferation and Irreversibility of Pulmonary Hypertension in Congenital Heart Disease J. Am. Coll. Cardiol., February 20, 2007; 49(7): 803 - 810. [Abstract] [Full Text] [PDF]

				W. C. Aird Phenotypic Heterogeneity of the Endothelium: II. Representative Vascular Beds Circ. Res., February 2, 2007; 100(2): 174 - 190. [Abstract] [Full Text] [PDF]

				N. W. Morrell Pulmonary Hypertension Due to BMPR2 Mutation: A New Paradigm for Tissue Remodeling? Proceedings of the ATS, November 1, 2006; 3(8): 680 - 686. [Abstract] [Full Text] [PDF]